GlassScriptPhysician profile
Olivia D Johnson
NPI 1770505141
$2,647.79
in general payments reported to CMS, 2019-2025
16 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $51.18 · 2023: $62.91 · 2024: $339 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300 · Travel and Lodging: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.57 |
| Travel and Lodging | $1,151.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,352.96 | 2025 | Iovera |
| Spinal Simplicity, LLC | $400.46 | 2024-2025 | Ha Minuteman G3-R |
| Forte Bio-Pharma LLC | $251.39 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Abbott Laboratories | $191.14 | 2021-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $90.90 | 2021-2024 | Xtampza, Belbuca |
| Medtronic, INC. | $64.24 | 2021-2023 | Vanta Adaptivestim |
| Protega Pharmaceutials INC | $61.58 | 2025 | Roxybond |
| Valinor Pharma, LLC | $45.94 | 2024-2025 | Movantik |
| Averitas Pharma INC. | $39.64 | 2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $36.96 | 2024-2025 | |
| Boston Scientific Corporation | $34.97 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.18 | 2025 | Gvoke Hypopen |
| Grt US Holding, INC. | $15.53 | 2021 | |
| Lilly USA, LLC | $14.90 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.54 | 2024 | Farxiga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.